Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
12.24
-0.10 (-0.81%)
At close: Aug 25, 2025, 4:00 PM
12.20
-0.04 (-0.33%)
After-hours: Aug 25, 2025, 7:49 PM EDT
Atara Biotherapeutics Employees
Atara Biotherapeutics had 153 employees as of December 31, 2024. The number of employees decreased by 72 or -32.00% compared to the previous year.
Employees
153
Change (1Y)
-72
Growth (1Y)
-32.00%
Revenue / Employee
$1,233,118
Profits / Employee
$37,876
Market Cap
85.97M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 153 | -72 | -32.00% |
| Dec 31, 2023 | 225 | -109 | -32.63% |
| Dec 31, 2022 | 334 | -244 | -42.21% |
| Dec 31, 2021 | 578 | 141 | 32.27% |
| Dec 31, 2020 | 437 | 44 | 11.20% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ATRA News
- 14 days ago - Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress - Business Wire
- 4 weeks ago - Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) - PRNewsWire
- 4 weeks ago - Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease - Business Wire
- 5 weeks ago - Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc. - PRNewsWire
- 6 weeks ago - Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®) - Business Wire
- 3 months ago - Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors - Business Wire
- 3 months ago - Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress - Business Wire
- 3 months ago - Atara Biotherapeutics Announces Pricing of $16 Million Offering - Business Wire